HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsDowngradesPrice Target
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.